Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf272 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2025. Verfasst von Iben Spanggaard und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen 2100, Denmark. Hauptthemen laut MEDLINE: Pyrimidines, Central Nervous System Neoplasms, Receptor, Fibroblast Growth Factor, Type 1, Pyrroles. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Academy of Neurology Annual Meeting, Incyte Corporation.
Abstract (Originalsprache)
Central nervous system (CNS) tumors often harbor alterations in genes regulating key cellular pathways, including fibroblast growth factor receptor (FGFR) genes. Here, we report the efficacy and safety of treatment with pemigatinib, an oral, potent, selective FGFR1-3 inhibitor, in patients with advanced FGFR-altered CNS tumors. FIGHT-207 was a single-arm, open-label, phase 2 study of pemigatinib in patients with advanced solid tumors harboring FGFR fusions/rearrangements or other mutations. Patients received pemigatinib 13.5 mg once daily until disease progression or unacceptable toxicity. Endpoints included tumor response and safety. Of the 13 patients with CNS tumors in FIGHT-207, 10 had glioblastoma. Fibroblast growth factor receptor alterations were FGFR3-TACC3 fusions (n = 9), FGFR1 K656E mutations (n = 2), FGFR1 N546K mutation (n = 1), and FGFR1-MITF fusion (n = 1). Three patients (23%) displayed objective responses (1 complete, 2 partial). Safety was consistent with the overall FIGHT-207 population. Pemigatinib had antitumor activity and a manageable safety profile in patients with CNS tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen 2100, Denmark.
- Ochsner Cancer Institute, Ochsner Clinic Foundation, New Orleans, LA 70121, United States.
- Department of Hematology and Oncology, Wake Forest University School of Medicine-Atrium Health, Winston-Salem, NC 27157, United States.
- Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States.
- Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, United States.
- Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona 08035, Spain.
ORCID-Profile: Iben Spanggaard
Förderung
- American Academy of Neurology Annual Meeting
- Incyte Corporation
Zitieren
APA
Spanggaard, I., Matrana, M., Rocha Lima, C., Mahipal, A., Vieito, M., Hervieu, A., Goyal, L., Rodón, J., Veronese, M. L., Oliveira, N., Li, X., Schaffer, M., & Kesari, S. (2025). Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results. The Oncologist. https://doi.org/10.1093/oncolo/oyaf272
Vancouver
Spanggaard I, Matrana M, Rocha Lima C, Mahipal A, Vieito M, Hervieu A, et al. Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results. The Oncologist. 2025. doi:10.1093/oncolo/oyaf272
BibTeX
@article{Spanggaard2025,
author = {Spanggaard, Iben and Matrana, Marc and Rocha Lima, Caio and Mahipal, Amit and Vieito, Maria and Hervieu, Alice and Goyal, Lipika and Rodón, Jordi and Veronese, Maria Luisa and Oliveira, Natalia and Li, Xin and Schaffer, Michael and Kesari, Santosh},
title = {Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf272}
}
EUVIMED